2025年,制药公司340B方案限制导致纽约医院收入损失8 000万美元,对低收入病人的护理构成威胁。 Pharmaceutical companies' 340B program restrictions caused $80M in lost revenue for NY hospitals in 2025, threatening care for low-income patients.

自2020年以来,制药公司限制340B药品定价方案,限制合同药店,导致安全网医院和诊所的收入急剧下降,包括申内克塔迪的艾利斯医院,该医院的340B收入下降了56%,从2019年的1 800万美元下降到2024年的不到800万美元。 Since 2020, pharmaceutical companies have restricted the 340B Drug Pricing Program, limiting contract pharmacies and causing a sharp revenue decline for safety-net hospitals and clinics, including Ellis Hospital in Schenectady, which saw its 340B income drop 56% from $18 million in 2019 to under $8 million in 2024. 仅2025年,这些变化就导致纽约保健中心的收入损失估计达8 000万美元,加重了已经运营的利润不足的医院的财政压力。 These changes have led to an estimated $80 million in lost revenue for New York health centers in 2025 alone, worsening financial strain on hospitals already operating with inadequate margins. 该方案允许购买折扣药品和全额保险报销,为低收入和无保险病人的肿瘤治疗等关键服务提供资金。 The program, which allows discounted drug purchases and full insurance reimbursement, funds critical services like oncology care for low-income and uninsured patients. 卫生领导人敦促立法者保护该计划, 防止服务不足的社区服务遭削减。 With looming Medicaid cuts and rising healthcare costs, health leaders are urging lawmakers to protect the program to prevent service cuts in underserved communities.